Process Development - Boehringer Ingelheim Therapeutics in Ochsenhausen, Germany
process development, services for vaccines, services for viral therapeutics, oncolytic for viral therapeutics, collaborations, industrial partners, gmp manufacturins, clinical studies, GMP certified facilities, GLP certified facilities, constant innovation, process technology
480
page-template,page-template-full_width,page-template-full_width-php,page,page-id-480,page-child,parent-pageid-412,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-6.6.0,vc_responsive

Process Development

Process Development

Boehringer Ingelheim Therapeutics performs numerous process development services for vaccines and viral therapeutics and is specialized early in the innovative and strongly upcoming field of viral gene therapeutics and oncolytic viral therapeutics. The multi-level expertise that is needed for developing up-stream as well as down-stream processes for new and innovative therapeutics are merged at Boehringer Ingelheim Therapeutics in a unique manner. The combination of the process development expertise and the GMP manufacturing capabilities at provides an ideal environment for successful end-to-end projects, culminating in material supply for phase I/II clinical studies.

 

The GMP and GLP certified facilities at Boehringer Ingelheim Therapeutics are an excellent origin of a successfully developed and manufactured product.

 

Constant innovation in development and process technology is stimulated by close collaboration with academic institutions.
Boehringer Ingelheim Therapeutics performs numerous process development services for vaccines and viral therapeutics and is specialized early in the innovative and strongly upcoming field of viral gene therapeutics and oncolytic viral therapeutics. The multi-level expertise that is needed for developing up-stream as well as down-stream processes for new and innovative therapeutics are merged at Boehringer Ingelheim Therapeutics in a unique manner. The combination of the process development expertise and the GMP manufacturing capabilities at provides an ideal environment for successful end-to-end projects, culminating in material supply for phase I/II clinical studies.

 

The GMP and GLP certified facilities at Boehringer Ingelheim Therapeutics are an excellent origin of a successfully developed and manufactured product.

 

Constant innovation in development and process technology is stimulated by close collaboration with academic institutions.